George Lolay, MD
Cardiovascular Disease · Indianapolis, INNPI 1811333941
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $88,501 of the $128,055 with a category attached, or 69.1%. E.r. Squibb & Sons, L.L.C. accounts for 92.2% of it on its own, with 30 other manufacturers making up the rest. 2025 is the largest year on record at $52,258, more than ten times the $871 reported in 2019. Among cardiovascular disease clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 348 payments — averaging $367.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$118K
- Abbott$4K
- Edwards Lifesciences$1K
- Johnson & Johnson$653
- AstraZeneca$542
- Novartis$540
- plus $3K from 25 others
Across 24 payments — averaging $5850.19 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$85K
- Boston Scientific$55K
What the payments were for
- Consulting fees$8,7657%
- Speaking & faculty fees$88,50169%
- Travel & lodging$22,07517%
- Food & beverage$8,4767%
- Education$2390%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 111 | $118,013 |
| Abbott | 32 | $3,833 |
| Edwards Lifesciences | 8 | $1,477 |
| Johnson & Johnson | 20 | $653 |
| AstraZeneca | 28 | $542 |
| Novartis | 34 | $540 |
| Heartflow, Inc. | 5 | $448 |
| Pfizer | 29 | $447 |
| Novo Nordisk | 11 | $316 |
| Amgen | 15 | $254 |
| Siemens Medical Solutions USA, Inc. | 2 | $228 |
| Astellas Pharma US Inc | 2 | $198 |
| Boehringer Ingelheim | 5 | $173 |
| Boston Scientific | 11 | $167 |
| Cardiovascular Systems Inc. | 1 | $128 |
| Merck | 8 | $123 |
| GE HealthCare | 1 | $79 |
| Kiniksa Pharmaceuticals International, PLC | 4 | $64 |
| Regeneron Healthcare Solutions, Inc. | 3 | $49 |
| Amarin Pharma, Inc. | 1 | $44 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $41 |
| Lexicon Pharmaceuticals, Inc. | 2 | $36 |
| Bayer | 2 | $35 |
| Scpharmaceuticals Inc. | 2 | $32 |
| Actelion Pharmaceuticals US, Inc. | 1 | $24 |
| Terumo Medical Corporation | 1 | $22 |
| Akcea Therapeutics, Inc. | 1 | $21 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $19 |
| Aegerion Pharmaceuticals, Inc. | 1 | $18 |
| Bridgebio Pharma, Inc. | 1 | $18 |
| Impulse Dynamics (USA) Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CAMZYOS$107,800
- MitraClip$1,530
- PASCAL$1,127
- TRICLIP$996
- XARELTO$359
- FFRct$301
- MitraClip System$264
- NAEOTOM Alpha$191
- Coronary Orbital Atherectomy System$128
- Peripheral Orbital Atherectomy System$128
- JARDIANCE$113
- Wegovy$110
How this compares
$128,055 in reported general payments places this provider in the 95th percentile of 408 cardiovascular disease providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 423 | $529,115 |
| EntrestoSacubitril/Valsartan | 254 | $333,178 |
| CamzyosMavacamten | 37 | $293,220 |
| JardianceEmpagliflozin | 131 | $173,033 |
| FarxigaDapagliflozin Propanediol | 109 | $135,429 |
| XareltoRivaroxaban | 66 | $99,200 |
| Repatha SureclickEvolocumab | 88 | $85,285 |
| VascepaIcosapent Ethyl | 32 | $28,130 |
| BrilintaTicagrelor | 17 | $17,097 |
| DapagliflozinDapagliflozin Propanediol | 11 | $9,551 |
| Metoprolol Succinate | 539 | $6,336 |
| Atorvastatin Calcium | 581 | $5,205 |
| Ezetimibe | 250 | $4,489 |
| Carvedilol | 386 | $3,320 |
| Rosuvastatin Calcium | 218 | $2,924 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $447 | $529,115423 claims |
| NovartisEntresto | $540 | $333,178254 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $118,013 | $293,22037 claims |
| Boehringer IngelheimJardiance | $173 | $173,033131 claims |
| AstraZenecaFarxiga, Brilinta | $542 | $152,526126 claims |
| Johnson & JohnsonXarelto | $653 | $99,20066 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 408 cardiovascular disease providers in Indiana.
Other cardiovascular disease in Indianapolis
- John MillerIndianapolis$354K
- David KovacichIndianapolis$327K
- Vijay RaoIndianapolis$247K
- Atul ChughIndianapolis$242K
- James TrippiIndianapolis$239K
- Christopher HealyIndianapolis$209K
- Richard KovacsIndianapolis$136K
- Onyedika IlonzeIndianapolis$125K
- Noel DasguptaIndianapolis$122K
- Anthony BashallIndianapolis$97K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.